Hypertension
Poster Session 4
Anne Reed-Weston, MD (she/her/hers)
Resident Physician
Christiana Care Health Systems
Newark, DE, United States
Lauren Roby, MD
Resident
Christiana Care Health Services
Newark, DE, United States
Dianne Holleran, MSN, RN
Christiana Care Health Systems
Newark, DE, United States
Matthew Hoffman, MD, MPH
Marie E. Pinizzotto, M.D., Endowed Chair of Obstetrics and Gynecology at Christiana Care
Christiana Care Health Systems
Newark, DE, United States
Postpartum women with hypertensive disorders are routinely discharged on Labetalol, Nifedipine, and Lasix; however, the impact of antihypertensive selection on readmission is not well understood.
Study Design:
We performed a retrospective cohort study of all pregnancies at a single institution who delivered from 07/31/2012 to 01/31/2023 who had a hypertensive disorder during pregnancy. Discharge antihypertensive medications were recorded along with other demographic data. Readmission within 42 days was then ascertained for the cohort. Our primary outcome was the readmission rate. Univariate analysis was performed.
Results:
A total of 11192 pregnancies met study criteria. The average maternal age was 30.1 and the study population was 55.78% white and 34.57% Black. 35.35% of the study cohort received health insurance funded by the government. A total of 491 patients were readmitted within 42 days of discharge, for a total readmission rate of 4.39%. Both Nifedipine and Lasix were associated with a statistically significant decreased risk of readmission, with readmission rates of 2.97% (p=0.04) and 3.45% (p=0.045) respectively. Receipt of labetalol was not associated with a change in readmission rate (5.12%, p=0.174).
Conclusion:
Discharge on Nifedipine or Lasix was associated with a statistically significant decrease in readmission rate, while receipt of Labetalol did not change readmission rates.